Literature DB >> 25122001

The role of dipeptidyl peptidase 4 (DPP4) in the preservation of renal function: DPP4 involvement in hemoglobin expression.

Youichi Sato1, Takanobu Kamada2, Aiko Yamauchi2.   

Abstract

In a previous study, we demonstrated that dipeptidyl peptidase 4 (DPP4)-deficient rats were susceptible to reduced glomerular filtration rate as a result of streptozotocin (STZ)-induced diabetes. Therefore, we proposed that DPP4 might be responsible for the preservation of renal function. In this study, to verify the role of DPP4 in the preservation of renal function, we performed a microarray analysis of the kidneys of WT and DPP4-deficient rats after STZ treatment, and gene expression analysis using rat kidneys, human embryonic kidney 293 (HEK293) cells, and human renal cancer cells (CakI-1). The microarray analysis indicated that the expression levels of the transporter activity, heme-binding, and pheromone binding-related genes changed significantly. The results of gene expression analysis indicated that there were no significant differences in the expression levels of hemoglobin mRNA between the DPP4-deficient and WT rats; however, the expression levels of hemoglobin mRNA in the kidneys of DPP4-deficient rats tended to decrease when compared with those of both the non-STZ-treated and STZ-treated WT rats. The expression levels of hemoglobin in HEK293 and Caki-1 cells were significantly decreased when DPP4 was knocked down by siRNA, were significantly increased by the addition of soluble human DPP4, and were also significantly increased by the addition of the DPP4 inhibitor, sitagliptin. The expression level of DPP4 was also significantly increased by the addition of sitagliptin in both cell types. Our findings indicate that DPP4 regulates the expression of the hemoglobin genes, and might play a role in the preservation of renal function; however, the underlying mechanism of this preservation remains to be elucidated.
© 2014 Society for Endocrinology.

Entities:  

Keywords:  DPP4 deficient; diabetes; hemoglobin; renal function; streptozotocin

Mesh:

Substances:

Year:  2014        PMID: 25122001     DOI: 10.1530/JOE-14-0016

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  4 in total

1.  Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial.

Authors:  Mohammad Amin Mohammad Zadeh Gharabaghi; Mohammad Reza Rezvanfar; Nasser Saeedi; Faezeh Aghajani; Mohammad Alirezaei; Pourya Yarahmadi; Amin Nakhostin-Ansari
Journal:  Clin Diabetes Endocrinol       Date:  2022-05-25

2.  DPP4 gene silencing inhibits proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through suppression of the MAPK pathway.

Authors:  X Hu; S Chen; C Xie; Z Li; Z Wu; Z You
Journal:  J Endocrinol Invest       Date:  2021-01-02       Impact factor: 4.256

3.  Dynamic Analysis of Kidney Function and Its Correlation with Nutritional Indicators in a Large Sample of Hospitalized Elderly Patients.

Authors:  Li Qingping; Wei Ribao; Wang Yang; Su Tingyu; Yang Xi; Huang Mengjie; Miao Hui; Chen Xiangmei
Journal:  Med Sci Monit       Date:  2017-04-23

4.  Long-term effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension: results from the PROLOGUE study.

Authors:  Ziliang Ye; Hui Li; Haili Lu; Qiang Su; Lang Li
Journal:  Oncotarget       Date:  2017-12-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.